Pharmaceuticals, Biotechnology and Life Sciences
Thermo Fisher Scientific has announced new Norwegian-based sales and services team to support customers at every stage of an instrument’s lifecycle, during installation and for any potential maintenance needs, to minimize instrument downtime.
Kynos Therapeutics Ltd has emerged from stealth mode with £9 million to finance its lead KMO inhibitor (KMOi) programme through Phase 1 clinical trials and to progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.
The European Commission (EC) has expanded the marketing authorization for Sanofi’s Dupixent (dupilumab) in the European Union to include treatment of children aged 6 to 11 years as an add-on maintenance treatment for uncontrolled severe asthma.
FDA said that GSK’s sotrovimab is not authorized in any U.S. state or territory at this time, as CDC’s data showed the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant.
Sandoz has announced the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
ViGeneron GmbH, a next-generation gene therapy company, has announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).
Nordic Nanovector ASA (OSE: NANOV) has announced that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company’s Annual General Meeting (AGM) on 28 April 2022.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Novartis-s Vijoice (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
Exscientia plc (Nasdaq: EXAI) has the appointed Michael Krams, M.D., as its Chief Quantitative Medicine Officer, to lead clinical development strategy for Exscientia’s portfolio of investigational medicines.
The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.